Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Visilizumab
(D06314)
1件: Visilizumab1件: Visilizumab (D06314) 💬3件: CD3D,
CD3E,
CD3G 💬
11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬2件: 96, 97 💬
2Visilizumab (HuM291
(D06314)
1件: Visilizumab1件: Visilizumab (D06314) 💬3件: CD3D,
CD3E,
CD3G 💬
11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 97 💬
3Visilizumab (Nuvion)
(D06314)
1件: Visilizumab1件: Visilizumab (D06314) 💬3件: CD3D,
CD3E,
CD3G 💬
11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 97 💬
4Visilizumab (Nuvion®
(D06314)
1件: Visilizumab1件: Visilizumab (D06314) 💬3件: CD3D,
CD3E,
CD3G 💬
11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 97 💬